News at CenExel

Placebo and Nocebo Response Mitigation

Empirical Strategies to Mitigate Placebo and Nocebo Effects CenExel sites are committed to enhancing understanding of the causes and implications of the placebo and nocebo effects within central nervous system and internal medicine clinical trials and developing...

Stuart Goldblatt Joins CenExel as CEO

Salt Lake City, July 17, 2023 /GlobeNewswire/ — The CenExel Board of Directors is delighted to announce that Stuart Goldblatt has joined CenExel as our new CEO effective July 17, 2023. Tom Wardle will transition to the role of Executive Chairman, CenExel Board of...

Michele Baptista Joins CenExel

Salt Lake City, May 18, 2023 /GlobeNewswire/ — CenExel announces the addition of Michele Baptista as the new Senior Director of Business Development. In this new capacity, Michele will be responsible for developing, selling, and supporting CenExel’s 18-site network...

Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia

CenExel is proud to announce that the work of David Walling, PhD, CEO and Principal Investigator at CenExel CNS, joined lead author, John H Krystal, as co-author of the recent Cerevel Therapeutics study titled, Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial, published in The Lancet.

CenExel CNS Opens Center in Los Alamitos, California

Los Alamitos, November 29, 2022 /GlobeNewswire/ — CenExel CNS announces the grand opening of the newest clinical research facility in Los Alamitos, California. CenExel CNS has been operating clinical research centers in the area since 2000, and this site will be the...